A key regulatory role for Vav1 in controlling lipopolysaccharide endotoxemia via macrophage-derived IL-6

Journal of Immunology

Volumn 192, Issue 6, 2014, Pages 2830-2836

  Zenker, Stefanie ^a   Panteleev Ivlev, Julia ^a   Wirtz, Stefan ^a   Kishimoto, Tadamitsu ^b   Waldner, Maximilian J ^a   Ksionda, Olga ^c,d   Tybulewicz, Victor L J ^c   Neurath, Markus F ^a   Atreya, Imke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATININE; GLUTAMATE DEHYDROGENASE; HEAT SHOCK TRANSCRIPTION FACTOR 1; INTERLEUKIN 6; PROTEIN VAV1; UNCLASSIFIED DRUG; VAV PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENZYME BLOOD LEVEL; GENE REPRESSION; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA; MACROPHAGE; MACROPHAGE ACTIVATION; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DNA-BINDING PROTEINS; ENDOTOXEMIA; GENE EXPRESSION; INTERLEUKIN-10; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; PROTO-ONCOGENE PROTEINS C-VAV; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897500535     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300157     Document Type: Article

References (43)

1. Karima, R., S. Matsumoto, H. Higashi, and K. Matsushima. 1999. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today 5: 123-132.
2. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885-891.
3. Gosemann, J. H., M. van Griensven, T. Barkhausen, P. Kobbe, B. M. Thobe, C. Haasper, H. C. Pape, C. Krettek, F. Hildebrand, and M. Frink. 2010. TLR4 influences the humoral and cellular immune response during polymicrobial sepsis. Injury 41: 1060-1067.
4. Hack, C. E., E. R. De Groot, R. J. Felt-Bersma, J. H. Nuijens, R. J. Strack Van Schijndel, A. J. Eerenberg-Belmer, L. G. Thijs, and L. A. Aarden. 1989. Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704-1710.
5. Damas, P., D. Ledoux, M. Nys, Y. Vrindts, D. De Groote, P. Franchimont, and M. Lamy. 1992. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann. Surg. 215: 356-362.
6. Katzav, S., D. Martin-Zanca, and M. Barbacid. 1989. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J. 8: 2283-2290.
7. Bustelo, X. R. 2001. Vav proteins, adaptors and cell signaling. Oncogene 20: 6372-6381.
8. Houlard, M., R. Arudchandran, F. Regnier-Ricard, A. Germani, S. Gisselbrecht, U. Blank, J. Rivera, and N. Varin-Blank. 2002. Vav1 is a component of transcriptionally active complexes. J. Exp. Med. 195: 1115-1127.
9. Tybulewicz, V. L. 2005. Vav-family proteins in T-cell signalling. Curr. Opin. Immunol. 17: 267-274.
10. Turner, M., P. J. Mee, A. E. Walters, M. E. Quinn, A. L. Mellor, R. Zamoyska, and V. L. Tybulewicz. 1997. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7: 451-460.
11. Tiede, I., G. Fritz, S. Strand, D. Poppe, R. Dvorsky, D. Strand, H. A. Lehr, S. Wirtz, C. Becker, R. Atreya, et al. 2003. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111: 1133-1145.
12. Poppe, D., I. Tiede, G. Fritz, C. Becker, B. Bartsch, S. Wirtz, D. Strand, S. Tanaka, P. R. Galle, X. R. Bustelo, and M. F. Neurath. 2006. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176: 640-651.
13. Fischer, K. D., A. Zmuldzinas, S. Gardner, M. Barbacid, A. Bernstein, and C. Guidos. 1995. Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes. Nature 374: 474-477.
14. Hall, A. B., M. A. Gakidis, M. Glogauer, J. L. Wilsbacher, S. Gao, W. Swat, and J. S. Brugge. 2006. Requirements for Vav guanine nucleotide exchange factors and Rho GTPases in FcgammaR- and complement-mediated phagocytosis. Immunity 24: 305-316.
15. Phillipson, M., B. Heit, S. A. Parsons, B. Petri, S. C. Mullaly, P. Colarusso, R. M. Gower, G. Neely, S. I. Simon, and P. Kubes. 2009. Vav1 is essential for mechanotactic crawling and migration of neutrophils out of the inflamed microvasculature. J. Immunol. 182: 6870-6878.
16. Spurrell, D. R., N. A. Luckashenak, D. C. Minney, A. Chaplin, J. M. Penninger, R. S. Liwski, J. L. Clements, and K. A. West. 2009. Vav1 regulates the migration and adhesion of dendritic cells. J. Immunol. 183: 310-318.
17. Miletic, A. V., D. B. Graham, V. Montgrain, K. Fujikawa, T. Kloeppel, K. Brim, B. Weaver, R. Schreiber, R. Xavier, and W. Swat. 2007. Vav proteins control MyD88-dependent oxidative burst. Blood 109: 3360-3368.
18. Wirtz, S., I. Tubbe, P. R. Galle, H. J. Schild, M. Birkenbach, R. S. Blumberg, and M. F. Neurath. 2006. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J. Exp. Med. 203: 1875-1881.
19. Yim, H. S., K. M. Choi, B. Kim, I. D. Jung, Y. M. Park, Y. K. Kang, and M. G. Lee. 2013. Effect of 1-methyl-D-tryptophan and adoptive transfer of dendritic cells on polymicrobial sepsis induced by cecal content injection. Microbiol. Immunol. 57: 633-639.
20. Van Rooijen, N. 1989. The liposome-mediated macrophage 'suicide' technique. J. Immunol. Methods 124: 1-6.
21. Inouye, S., H. Izu, E. Takaki, H. Suzuki, M. Shirai, Y. Yokota, H. Ichikawa, M. Fujimoto, and A. Nakai. 2004. Impaired IgG production in mice deficient for heat shock transcription factor 1. J. Biol. Chem. 279: 38701-38709.
22. Ksionda, O., A. Saveliev, R. Köchl, J. Rapley, M. Faroudi, J. E. Smith-Garvin, C. Wülfing, K. Rittinger, T. Carter, and V. L. Tybulewicz. 2012. Mechanism and function of Vav1 localisation in TCR signalling. J. Cell Sci. 125: 5302-5314.
23. Costello, P. S., A. E. Walters, P. J. Mee, M. Turner, L. F. Reynolds, A. Prisco, N. Sarner, R. Zamoyska, and V. L. Tybulewicz. 1999. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways. Proc. Natl. Acad. Sci. USA 96: 3035-3040.
24. Upshaw, J. L., L. N. Arneson, R. A. Schoon, C. J. Dick, D. D. Billadeau, and P. J. Leibson. 2006. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 7: 524-532.
25. David, R., L. Ma, A. Ivetic, A. Takesono, A. J. Ridley, J. G. Chai, V. L. Tybulewicz, and F. M. Marelli-Berg. 2009. T-cell receptor- and CD28-induced Vav1 activity is required for the accumulation of primed T cells into antigenic tissue. Blood 113: 3696-3705.
26. Weckbecker, G., C. Bruns, K. D. Fischer, C. Heusser, J. Li, B. Metzler, R. E. Morris, B. Nuesslein-Hildesheim, F. Raulf, G. Wieczorek, and G. Zenke. 2007. Strongly reduced alloreactivity and long-term survival times of cardiac allografts in Vav1- and Vav1/Vav2-knockout mice. Transpl. Int. 20: 353-364.
27. Cavaillon, J. M., and M. Adib-Conquy. 2005. Monocytes/macrophages and sepsis. Crit. Care Med. 33(12, Suppl.)S506-S509.
28. Verdrengh, M., and A. Tarkowski. 2000. Role of macrophages in Staphylococcus aureus-induced arthritis and sepsis. Arthritis Rheum. 43: 2276-2282.
29. Inouye, S., M. Fujimoto, T. Nakamura, E. Takaki, N. Hayashida, T. Hai, and A. Nakai. 2007. Heat shock transcription factor 1 opens chromatin structure of interleukin-6 promoter to facilitate binding of an activator or a repressor. J. Biol. Chem. 282: 33210-33217.
30. Mostafa Anower, A. K., J. A. Shim, B. Choi, and S. Sohn. 2012. Pretreatment with interleukin-6 small interfering RNA can improve the survival rate of polymicrobial cecal ligation and puncture mice by down regulating interleukin-6 production. Eur. J. Pharmacol. 688: 76-83.
31. Barkhausen, T., T. Tschernig, P. Rosenstiel, M. van Griensven, R. P. Vonberg, M. Dorsch, A. Mueller-Heine, A. Chalaris, J. Scheller, S. Rose-John, et al. 2011. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit. Care Med. 39: 1407-1413.
32. Riedemann, N. C., T. A. Neff, R. F. Guo, K. D. Bernacki, I. J. Laudes, J. V. Sarma, J. D. Lambris, and P. A. Ward. 2003. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170: 503-507.
33. Pallua, N., J. F. Low, and D. von Heimburg. 2003. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model. Crit. Care Med. 31: 1495-1501.
34. Patel, R. T., K. I. Deen, D. Youngs, J. Warwick, and M. R. Keighley. 1994. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br. J. Surg. 81: 1306-1308.
35. Deutschman, C. S., M. Cereda, E. A. Ochroch, and N. R. Raj. 2006. Sepsisinduced cholestasis, steatosis, hepatocellular injury, and impaired hepatocellular regeneration are enhanced in interleukin-62/2 mice. Crit. Care Med. 34: 2613-2620.
36. Inoue, K., H. Takano, R. Yanagisawa, M. Sakurai, A. Shimada, M. Satoh, S. Yoshino, K. Yamaki, and T. Yoshikawa. 2008. Antioxidative role of interleukin-6 in septic lung injury in mice. Int. J. Immunopathol. Pharmacol. 21: 501-507.
37. Remick, D. G., G. Bolgos, S. Copeland, and J. Siddiqui. 2005. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect. Immun. 73: 2751-2757.
38. O'Malley, K., and L. L. Moldawer. 2006. Interleukin-6: Still crazy after all these years. Crit. Care Med. 34: 2690-2691.
39. Fink, M. P. 2006. The prevention and treatment of sepsis: is interleukin-6 a drug target or a drug? Crit. Care Med. 34: 919-921.
40. Scheller, J., A. Chalaris, D. Schmidt-Arras, and S. Rose-John. 2011. The proand anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813: 878-888.
41. Yoo, A. S., and I. Greenwald. 2005. LIN-12/Notch activation leads to microRNA-mediated down-regulation of Vav in C. elegans. Science 310: 1330-1333.
42. Panacek, E. A., J. C. Marshall, T. E. Albertson, D. H. Johnson, S. Johnson, R. D. MacArthur, M. Miller, W. T. Barchuk, S. Fischkoff, M. Kaul, et al; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. 2004. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab9)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32: 2173-2182.
43. Connor, V. 2011. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol. Int. 31: 327-337.